Novarex Co

Novarex Co EBITDA per Share

The EBITDA per Share of Novarex Co (194700.KQ) as of Nov 3, 2026 is 2,537.80 KRW. In the previous year, EBITDA per Share was 1,571.36 KRW — a change of 61.50% (higher).

EBITDA per Share

2,537.80KRW

YoY

61.50%

Last updated:

EBITDA per Share of Novarex Co is 2025 2,537.80 KRW. EBITDA per Share of Novarex Co was 2024 1,571.36 KRW. It decreases by 61.50% higher compared to the previous year.

The Novarex Co EBITDA per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Share
Date
EBITDA per Share
Jan 1, 2017
648.00 KRW
Jan 1, 2018
1,415.38 KRW
Jan 1, 2019
2,102.83 KRW
Jan 1, 2020
1,701.13 KRW
Jan 1, 2021
1,971.56 KRW
Jan 1, 2022
1,447.18 KRW
Jan 1, 2023
1,571.36 KRW
Jan 1, 2025
2,537.80 KRW
The Novarex Co EBITDA per Share history
YEAREBITDA per ShareYoY
2,537.80KRW+61.50%
1,571.36KRW+8.58%
1,447.18KRW-26.60%
1,971.56KRW+15.90%
1,701.13KRW-19.10%
2,102.83KRW+48.57%
1,415.38KRW+118.42%
648.00KRW-2.76%
666.42KRW-7.93%
723.84KRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Novarex Co Stock analysis

What does Novarex Co do? Novarex Co Ltd manufactures and sells dietary supplements including vitamin and mineral products, body fat reduction solutions, eye health aids, joint health products, lactic acid bacteria for skin improvement, coenzyme Q10, wild mango seed extract, and spirulina. The company distributes these products domestically in Korea and internationally. Its primary customers are consumers seeking health functional foods and nutritional supplements. The firm focuses on branded products that target specific health concerns such as body fat, eye health, and joint care. Novarex Co Ltd's revenue streams come from the sale of its diverse supplement portfolio to both domestic and international markets. The company's product range includes individual recognition products designed for specific health benefits, alongside general nutritional supplements. Sales are driven by consumer demand for health-focused functional foods and dietary supplements in the Korean market and overseas. The company's manufacturing and distribution operations support its product lines, which include specialized items like wild mango seed extract and spirulina. These products cater to health-conscious consumers looking for natural solutions for body fat reduction, eye health, and skin conditions. Novarex Co Ltd's business model relies on direct sales of branded supplements to end consumers through domestic and international channels. Novarex Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Novarex Co stock

EBITDA per Share of Novarex Co is 2,537.80 KRW in 2025.

EBITDA per Share of Novarex Co changed from 1,571.36 KRW to 2,537.80 KRW, representing a 61.50% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Share Novarex Co since 2006 – with annual values, charts, and detailed analysis.

EBITDA per share divides EBITDA by shares outstanding, showing the operating cash earnings allocated to each share before depreciation and financing effects.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Novarex Co

All Key Metrics — Novarex Co